` ITOS (Iteos Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ITOS
vs
S&P 500

Over the past 12 months, ITOS has outperformed S&P 500, delivering a return of +26% compared to the S&P 500's +16% growth.

Stocks Performance
ITOS vs S&P 500

Loading
ITOS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ITOS vs S&P 500

Loading
ITOS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ITOS vs S&P 500

Loading
ITOS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Iteos Therapeutics Inc vs Peers

S&P 500
ITOS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Iteos Therapeutics Inc
Glance View

Market Cap
448.7m USD
Industry
Biotechnology

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

ITOS Intrinsic Value
0.46 USD
Overvaluation 95%
Intrinsic Value
Price
Back to Top